Zobrazeno 1 - 10
of 158
pro vyhledávání: '"Tohru Ohmori"'
Autor:
Koichi Ando, Ryo Manabe, Yasunari Kishino, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori, Tsukasa Ohnishi, Hironori Sagara
Publikováno v:
Current Oncology, Vol 28, Iss 2, Pp 1094-1113 (2021)
Improving therapeutic strategies for extensive-stage small cell lung cancer (ES-SCLC) remains a challenge. To date, no reports have directly compared the efficacy and safety of immune checkpoint inhibitors plus platinum–etoposide (ICIs+EP) with pla
Externí odkaz:
https://doaj.org/article/5bd50b60997243feb6a4db0bd33e6a4d
Autor:
Koichi Ando, Ryo Manabe, Yasunari Kishino, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori, Hironori Sagara
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 3, p 2242 (2023)
Central nervous system (CNS) metastases and acquired resistance complicate the treatment of anaplastic lymphoma kinase (ALK) rearrangement-positive (ALK-p) advanced non-small cell lung cancer (NSCLC). Thus, this review aimed to provide a comprehensiv
Externí odkaz:
https://doaj.org/article/8ea72489cc5d4cb4a3ed48590aadbb08
Autor:
Shigetoshi Nishihara, Toshimitsu Yamaoka, Fumihiro Ishikawa, Kensuke Higuchi, Yuki Hasebe, Ryo Manabe, Yasunari Kishino, Sojiro Kusumoto, Koichi Ando, Yusuke Kuroda, Tohru Ohmori, Hironori Sagara, Hitoshi Yoshida, Junji Tsurutani
Publikováno v:
Genes, Vol 13, Iss 12, p 2183 (2022)
Homeostasis is achieved by balancing cell survival and death. In cancer cells, especially those carrying driver mutations, the processes and signals that promote apoptosis are inhibited, facilitating the survival and proliferation of these dysregulat
Externí odkaz:
https://doaj.org/article/97759817539143eaa4baa1fe5593567c
Autor:
Shigetoshi Nishihara, Toshimitsu Yamaoka, Fumihiro Ishikawa, Tohru Ohmori, Koichi Ando, Sojiro Kusumoto, Yasunari Kishino, Ryo Manabe, Yuki Hasebe, Hironori Sagara, Hitoshi Yoshida, Junji Tsurutani
Publikováno v:
Cells, Vol 11, Iss 14, p 2201 (2022)
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is used as a first-line treatment for patients with EGFR-mutant non-small cell lung cancer (NSCLC). However, the mechanisms underlying its antica
Externí odkaz:
https://doaj.org/article/cafd1222792e4fe19b6a94a44c4791b0
Autor:
Koichi Ando, Ryo Manabe, Yasunari Kishino, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori, Hironori Sagara
Publikováno v:
Cancers, Vol 13, Iss 15, p 3704 (2021)
To date, there have been no head-to-head randomized controlled trials (RCTs) comparing the safety and efficacy of lorlatinib and alectinib in anaplastic lymphoma kinase (ALK) rearrangement-positive (ALK-p) ALK-inhibitor‒naïve advanced non-small ce
Externí odkaz:
https://doaj.org/article/753f5f39686f4a9cb022c3044a225097
Autor:
Tohru Ohmori, Toshimitsu Yamaoka, Koichi Ando, Sojiro Kusumoto, Yasunari Kishino, Ryou Manabe, Hironori Sagara
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 2, p 792 (2021)
The tyrosine kinase activity of epidermal growth factor receptors (EGFRs) plays critical roles in cell proliferation, regeneration, tumorigenesis, and anticancer resistance. Non-small-cell lung cancer patients who responded to EGFR-tyrosine kinase in
Externí odkaz:
https://doaj.org/article/efc2a5d7928744cbb9143ee858846ad6
Autor:
Koichi Ando, Ryo Manabe, Yasunari Kishino, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori, Tsukasa Ohnishi, Hironori Sagara
Publikováno v:
Cancers, Vol 13, Iss 1, p 52 (2020)
The efficacy and safety of immune checkpoint inhibitors (ICIs) in refractory or relapsed advanced non-small-cell lung cancer (NSCLC) have not yet been compared with those of ramucirumab (Ram) plus docetaxel (Doc). Furthermore, comprehensive compariso
Externí odkaz:
https://doaj.org/article/31b0129997e642bfbdeb13745ae686f4
Publikováno v:
Biochemistry and Biophysics Reports, Vol 5, Iss C, Pp 1-7 (2016)
Syndecan-4 (SDC4) is a cell-surface proteoglycan associated with cell adhesion, motility, and intracellular signaling. Here, we present that SDC4 functions as a positive regulator of the transforming growth factor (TGF)-β1-induced epithelial to mese
Externí odkaz:
https://doaj.org/article/fc78142e05d94075b28869f886027c8c
Autor:
Tomoki Uno, Tetsuya Homma, Masahiko Shigemura, Yosuke Fukuda, Tomoyuki Kimura, Chihiro Onitsuka, Tomoko Kawahara, Hiroki Sato, Kaho Akimoto, Hiromitsu Suganuma, Ayaka Kashima, Shigenori Yamamoto, Takaya Ebato, Tomohiro Matsunaga, Keisuke Kaneko, Hatsuko Mikuni, Haruna Sato, Yoshitaka Uchida, Akiko Fujiwara, Naota Kuwahara, Ryo Manabe, Hitomi Ida, Kuniaki Hirai, Yoshito Miyata, Megumi Jinno, Shin Ohta, Yasunari Kishino, Hideki Inoue, Mayumi Yamamoto, Yoshio Watanabe, Sojiro Kusumoto, Koichi Ando, Shintaro Suzuki, Akihiko Tanaka, Tohru Ohmori, Hironori Sagara
Publikováno v:
Journal of Clinical Medicine, Vol 9, Iss 9, p 2819 (2020)
Chronic obstructive pulmonary disease (COPD) is a respiratory illness characterized by airflow limitation and chronic respiratory symptoms with a global prevalence estimated to be more than 10% in 2010 and still on the rise. Furthermore, hypercapnic
Externí odkaz:
https://doaj.org/article/63c56c4afc0145ec8f24a3d6bec6b7b9
Autor:
Koichi Ando, Yasunari Kishino, Tetsuya Homma, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori, Tsukasa Ohnishi, Hironori Sagara
Publikováno v:
Cancers, Vol 12, Iss 7, p 1905 (2020)
No head-to-head trials have compared the efficacy and safety of nivolumab (Niv) plus ipilimumab (Ipi) combination therapy (Niv+Ipi) and existing regimens with immunotherapies approved as first-line treatment in patients with programmed cell death lig
Externí odkaz:
https://doaj.org/article/da0fa3f6755b4e0a9be144acf4a61b3b